PT-141

PT-141 refers to bremelanotide, studied for a specific sexual-desire disorder. Evidence from a regulated overseas medicine does not establish the safety or approval of a product in New Zealand.

Human evidenceResearch added: 29 October 2026

Check the identity first.

PT141 is listed here as bremelanotide, but product identity still requires a regulated product record.

Why the interest?

PT-141 is commonly associated with bremelanotide.

Sexual wellbeing

Claims you may come across

Reported benefits, not product promises

Increased sexual desire.
Broader sexual-performance claims.

Personal stories are anecdotal. They cannot show whether a product caused a change, how often it happens or what the risks are.

How much is backed up?

There is human trial evidence for bremelanotide in a narrow, defined diagnosis: acquired, generalised hypoactive sexual desire disorder in premenopausal women. It does not support broad performance claims, other groups, or an unverified PT141 product.

Research context: FDA: Vyleesi prescribing information

PT-141 and bremelanotide

PT-141 is commonly associated with bremelanotide. The strongest human evidence concerns a specific, regulated US medicine for a defined diagnosis. That does not establish the identity, quality, approval or suitability of a product marketed under a PT141 label.

Two phase 3 trials studied a defined population

In 2019, two placebo-controlled phase 3 trials randomised 1,267 premenopausal women with hypoactive sexual desire disorder, persistent low sexual desire that causes distress. Bremelanotide improved desire and distress measures. Nausea, flushing and headache were more common than with placebo. The pooled safety and efficacy populations were 1,247 and 1,202 women, respectively.

Bremelanotide for hypoactive sexual desire disorder: two randomised phase 3 trials (2019)

The FDA indication is narrower than broad sexual-performance claims

The FDA approved Vyleesi, containing bremelanotide, in 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Its prescribing information excludes use for postmenopausal women, men, and desire problems due to medical, psychiatric, relationship, or medicine-related causes.

FDA Vyleesi prescribing information (2019)

What this tells us

This is evidence for a specific medicine and diagnosis, not a general-purpose sexual enhancer. A PT141 label alone does not confirm bremelanotide or replicate the regulated product studied.

What’s being studied?

Acquired, generalised hypoactive sexual desire disorder in premenopausal women

Research topics are not a promise of benefits.

What we know

FDA labelling for Vyleesi identifies bremelanotide and its limited approved US indication.

What we don’t know

That overseas label does not verify products sold under PT141, establish NZ approval or support broader sexual-performance claims.

Risks worth understanding.

Nausea
Temporary blood-pressure increase and heart-rate reduction
Hyperpigmentation
Injection-product contamination risk

This is not a complete list of risks or a personal safety assessment.

Already have a product?

Keep its packaging and ingredient information. Check the formulation, instructions and supplies together. An unidentified product cannot be made safe by an online dose calculation.

Before mixing: checks & supplies

Context matters.

Medsafe warns that unapproved products supplied outside the regulated medicines system are illegal and potentially harmful.

“Research purposes only” is not a legal exemption or a safety guarantee. This guide is for research and educational purposes only and does not recommend taking this substance.

Read Medsafe’s warning

Common questions

The things you might be wondering.

Why is PT141 shown under bremelanotide?

That is the supplied association, not independent verification that a product contains bremelanotide.

What has bremelanotide been studied for?

Its FDA label is limited to acquired, generalised HSDD in premenopausal women, with important exclusions.

Is there a safe dose I can use?

There is no universal safe dose. Any treatment needs a clinician and a confirmed regulated product.

Read it at the source.

Keep the conversation going

Two perspectives on the wider peptide conversation. These episodes provide context; they do not identify or validate a product with this label. Pick a thumbnail to watch here.

Huberman Lab · 1 April 2024

Peptide Benefits & Risks with Andrew Huberman

A useful starting point for the peptide conversation. Andrew Huberman talks through repair-related peptides, growth-hormone pathways and PT-141, alongside sourcing, side effects and the limits of the evidence. Listen for the difference between a promising idea and a result tested in people.

Play loads the YouTube player. Podcast discussion is context, not medical advice.

Episode & transcript

Huberman Lab · 1 June 2026

Peptide Science & Safety with Dr Abud Bakri

Why are peptides getting so much attention? Dr Abud Bakri joins Andrew Huberman to discuss BPC-157, GHK-Cu, melanotan and GLP-1 medicines. They explore what is being studied, why product sourcing matters and where animal findings still need to be tested in humans.